Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco

Rhea-AI Summary

Phio Pharmaceuticals (Nasdaq: PHIO) announced that its Principal Executive Officer, Robert Bitterman, will present at the Entrepreneurial Showcase during the Dermatology Summit in San Francisco on January 8, 2023. He will highlight the company's proprietary INTASYL^™ RNAi platform, which aims to enhance the effectiveness of immune cells against tumor cells. INTASYL is distinguished as the only self-delivering RNAi technology tailored for immuno-oncology therapeutics. Bitterman has a history of leading dermatological product development and commercialization.

Positive

• Robert Bitterman to present innovations in dermatological cancers, representing Phio Pharmaceuticals.
• INTASYL^™ RNAi platform showcased as a unique self-delivering technology in immuno-oncology.

Negative

• None.

MARLBOROUGH, Mass., Jan. 6, 2023 /PRNewswire/ -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL^™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that its Principal Executive Officer and Executive Chairman, Robert Bitterman, will be a featured speaker at the Entrepreneurial Showcase at the Dermatology Summit in San Francisco on January 8th. The Dermatology Summit is taking place at the Hyatt Regency, alongside the annual JPMorgan Healthcare Conference.

Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg

Mr. Bitterman will discuss innovations in dermatological cancers, highlighting Phio's proprietary INASTYL^™ platform. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics.

Mr. Bitterman was recently appointed to his leadership role at Phio. He previously led Cutanea and Dermik in the development and commercialization of small molecule dermatological products.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL^™ RNAi technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

For additional information, visit the Company's website, www.phiopharma.com.

Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com  

Investor Contact
Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com 

View original content:https://www.prnewswire.com/news-releases/phio-showcases-innovations-in-dermatology-cancers-at-2023-dermatology-summit-in-san-francisco-301715760.html

SOURCE Phio Pharmaceuticals Corp.

FAQ

What is Phio Pharmaceuticals presenting at the Dermatology Summit?

Phio Pharmaceuticals is showcasing its INTASYL^™ RNAi platform for enhancing immune cell effectiveness against tumors.

When is Robert Bitterman's presentation at the Dermatology Summit scheduled?

Robert Bitterman's presentation is scheduled for January 8, 2023, at the Dermatology Summit in San Francisco.

What does the INTASYL^™ RNAi platform do?

INTASYL^™ RNAi platform is designed to make immune cells more effective in killing tumor cells and is the only self-delivering RNAi technology in immuno-oncology.